Kalaris Therapeutics, Inc. NGM · KLRS
Price alert —
Sign in to get a one-time email the moment KLRS crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · KLRS
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare KLRS vs peers
Line KLRS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with KLRS
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 5 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-12 | -0.46 | -0.52 | +12.1% | +0.8% |
| 2026-03-17 | -0.44 | -0.55 | +20.0% | -11.6% |
| 2025-11-12 | -0.64 | -0.61 | -4.5% | +7.5% |
| 2025-08-13 | -0.61 | -0.52 | -17.3% | -0.4% |
| 2025-05-14 | -2.52 | -0.77 | -225.2% | +4.7% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| KLRS ★ | $0B | — | -2.7 | — | — | 1.5 | — | — | — | -26.12% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 29.8 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.4 | 0.9 | 20.2 | 4.0 | 18.8% | 2.0% | 0.7% | 4.57% |
| JNJ | $609B | 29.4 | 19.7 | 6.2 | 18.2 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.9 | 13.2 | 4.8 | 12.2 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.1 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.7 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.3 | 19.5 | 4.4 | 21.4 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 71.95%
| Holder | Shares | % out |
|---|---|---|
| Samsara BioCapital, LLC | 12,948,081 | 54.42% |
| RTW Investments LP | 1,300,000 | 5.46% |
| Paradigm Biocapital Advisors LP | 700,000 | 2.94% |
| Alyeska Investment Group, L.p. | 572,687 | 2.41% |
| Siren, L.L.C. | 435,798 | 1.83% |
| Ikarian Capital, LLC | 360,000 | 1.51% |
| Propel Bio Management, LLC | 295,771 | 1.24% |
| Vanguard Capital Management LLC | 255,348 | 1.07% |
| Kalehua Capital Management LLC | 135,585 | 0.57% |
| Raymond James Financial, Inc. | 118,887 | 0.50% |
Insider activity · 90d
8 buys / 0 sells · ratio 8.0 · Finnhub
- Ferrara Napoleone BUY 9,000
- Dybbs Michael BUY 9,000
- Jovan-Embiricos Morana BUY 9,000
- Hallal David BUY 9,000
- ADAMIS ANTHONY P BUY 9,000
- AKKARAJU SRINIVAS BUY 9,000
- PATTERSON LEONE D BUY 9,000
- AKKARAJU SRINIVAS J 19,408
- AKKARAJU SRINIVAS J 14,937
- AKKARAJU SRINIVAS J 10,657,028
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
No CIK found for KLRS.
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Options picks · KLRS
ITM + OTM ideas from the latest scanLoading…
Congress trades · KLRS
STOCK Act disclosuresLoading…
SEC filings & insiders · KLRS
EDGAR · liveLoading…
Holders · KLRS
Institutions & insider activityLoading…